Literature DB >> 12845480

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.

H Goldschmidt1, P Sonneveld, F W Cremer, B van der Holt, P Westveer, I Breitkreutz, A Benner, A Glasmacher, I G D Schmidt-Wolf, H Martin, D Hoelzer, A D Ho, H M Lokhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12845480     DOI： 10.1007/s00277-003-0685-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  15 in total

1.  The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

Authors:  Gerlinde Egerer; Kathrin Eisenlohr; Martina Gronkowski; Juergen Burhenne; Klaus-Dieter Riedel; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

2.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Authors:  Sarah Waheed; Alan Mitchell; Saad Usmani; Joshua Epstein; Shmuel Yaccoby; Bijay Nair; Rudy van Hemert; Edgardo Angtuaco; Tracy Brown; Twyla Bartel; James McDonald; Elias Anaissie; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Authors:  Alboukadel Kassambara; Dirk Hose; Jérôme Moreaux; Brian A Walker; Alexei Protopopov; Thierry Reme; Franck Pellestor; Véronique Pantesco; Anna Jauch; Gareth Morgan; Hartmut Goldschmidt; Bernard Klein
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

5.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

6.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

7.  Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Authors:  H Goldschmidt; H M Lokhorst; E K Mai; B van der Holt; I W Blau; S Zweegman; K C Weisel; E Vellenga; M Pfreundschuh; M J Kersten; C Scheid; S Croockewit; R Raymakers; D Hose; A Potamianou; A Jauch; J Hillengass; M Stevens-Kroef; M S Raab; A Broijl; H W Lindemann; G M J Bos; P Brossart; M van Marwijk Kooy; P Ypma; U Duehrsen; R M Schaafsma; U Bertsch; T Hielscher; Le Jarari; H J Salwender; P Sonneveld
Journal:  Leukemia       Date:  2017-07-04       Impact factor: 11.528

8.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20

9.  Front line treatment of elderly multiple myeloma in the era of novel agents.

Authors:  Marie-Dominique Venon; Aldo M Roccaro; Julie Gay; Anne-Sophie Moreau; Remy Dulery; Thierry Facon; Irene M Ghobrial; Xavier Leleu
Journal:  Biologics       Date:  2009-07-13

10.  Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Tobias Meissner; Jérôme Moreaux; Anja Seckinger; Joe Lewis; Vladimir Benes; Axel Benner; Michael Hundemer; Thomas Hielscher; John D Shaughnessy; Bart Barlogie; Kai Neben; Alwin Krämer; Jens Hillengass; Uta Bertsch; Anna Jauch; John De Vos; Jean-François Rossi; Thomas Möhler; Jonathon Blake; Jürgen Zimmermann; Bernard Klein; Hartmut Goldschmidt
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.